Latest News

bluebird bio Reports Second Quarter 2019 Financial Results and Highlights Operational Progress

CAMBRIDGE, Mass.–(BUSINESS WIRE)–bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the second quarter ended June 30, 2019. “With the approval of our first gene therapy, bluebird bio has entered into an exciting, and potentially transformative time for patients and for the company. We are focused on getting our qualified treatment centers up and running in Europe, ensuring we are prepared to deliver ZYNTEGLO to patients, and advancing the implementa

Source link

Related posts

Exploring gender gap and school differential effects in mathematics in Chilean primary schools


Samenvatting: Concept Medical is CE-gecertificeerd voor hun Sirolimus gecoate MagicTouch productgroep


Triglyceride-containing lipoprotein sub-fractions and risk of coronary heart disease and stroke: A prospective analysis in 11,560 adults


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy